- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.04. | AstraZeneca unfolds first DTC TV ad for breast cancer med Truqap | ||
| 30.04. | Sanofi nets €10B from Opella sale, eyes more 'bolt-on' deals | ||
| 30.04. | As vaccine sales slip, GSK touts 'mitigation options' for potential drug tariffs | ||
| 30.04. | J&J joins Argenx, UCB in the myasthenia gravis arena with FDA approval for FcRn blocker Imaavy | ||
| 30.04. | Charles Barkley boards Ro's GLP-1 ad push, signing up to take a 2nd shot at weight loss | ||
| 29.04. | Gilead enters $202M settlement to resolve US government's long-running HIV kickbacks probe | ||
| 29.04. | AstraZeneca's highly touted Truqap flunks another phase 3 trial | ||
| 29.04. | Bipartisan House lawmakers try again to cut tax breaks for DTC drug ads | ||
| 29.04. | Regeneron's Eylea franchise suffers double whammy with sales decline and surprise FDA rejection | ||
| 29.04. | Pfizer, in sweeping cost cutting push, lifts overall savings target to $7.7B | ||
| 29.04. | Novo moves past GLP-1 spat with Hims & Hers, tapping telehealth company to offer discounted Wegovy | ||
| 29.04. | As Novartis builds momentum with new drug launches, CEO says he's 'comfortable' navigating US tariffs | ||
| 29.04. | Merck begins construction on $1B Keytruda manufacturing facility in Delaware | ||
| 29.04. | Abeona enters commercial gene therapy arena with FDA nod for Zevaskyn to treat rare genetic skin disease | ||
| 29.04. | Bayer gets industry discredit ruling overturned after accusation of 'warming the market' for Eylea launch | ||
| 28.04. | Daiichi Sankyo, AstraZeneca's highly touted ADC Datroway off to 'smooth market launch' | ||
| 28.04. | PCI's expansion tear rolls on with acquisition of fill-finish CDMO Ajinomoto Althea | ||
| 28.04. | Delivering Hope: Building a Network to Deliver Radioligand Therapies | ||
| 28.04. | AACR: Merck's Keytruda prevents head and neck cancer from returning in industry-first win | ||
| 28.04. | Merck KGaA springs back into M&A game with $3.9B buyout of Pfizer spinout SpringWorks | ||
| 28.04. | French health authorities suspend use of Valneva's chikungunya vaccine in older adults to probe 3 hospitalizations, one death | ||
| 28.04. | Regeneron scores EU nod for bispecific antibody Lynozyfic, setting up clash with J&J and Pfizer | ||
| 28.04. | 'Deviated from core': Akeso CEO tries to reset expectations of bispecific's survival readout amid market tumult | ||
| 27.04. | As J&J aims to 'fundamentally change' how bladder cancer type is treated, ImmunityBio plays defense | ||
| 25.04. | Summit stock crashes as Akeso shares bispecific's first overall survival data in Keytruda head-to-head trial |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .